Comparison Between Antidiabetic Weight Loss Medication

References

[1] Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Kushner, R. F. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038New England Journal of Medicine

[2] Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183New England Journal of Medicine

[3] Frias, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & Tirzepatide Study Group. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519New England Journal of Medicine

[4] Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & Wadden, T. A. (2022). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA, 327(14), 1389–1399. https://doi.org/10.1001/jama.2022.3404

[5] Kadowaki, T., Haneda, M., Inagaki, N., Terauchi, Y., Taniguchi, A., Iwamoto, Y., ... & Araki, E. (2021). Efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 23(1), 76–85. https://doi.org/10.1111/dom.14189

[6] Neeland, I. J., Eliasson, B., Kasichayanula, S., Takami, K., & Wanner, C. (2021). The impact of empagliflozin on weight and body composition in patients with type 2 diabetes: A randomized controlled trial. Diabetes, Obesity and Metabolism, 23(3), 664–673. https://doi.org/10.1111/dom.14265

[7] Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Chiang, Y., ... & Surpass-2 Investigators. (2021). Efficacy and safety of tirzepatide versus semaglutide in patients with type 2 diabetes: A randomized, double-blind, phase 3 trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6

[8] Frias, J. P., Nauck, M. A., Van J, A., Kulich, K., Liu, B., Hartman, R., & Milicevic, Z. (2021). Efficacy and safety of oral semaglutide versus placebo added to insulin in type 2 diabetes: A 52-week, randomized, double-blind, phase 3 trial. The Lancet Diabetes & Endocrinology, 9(9), 563–574. https://doi.org/10.1016/S2213-8587(21)00170-0

[9] Kapitza, C., Nosek, L., Jensen, L., Hartvig, H., Jensen, C. B., & Flint, A. (2021). Semaglutide, a once-weekly human GLP-1 analog, does not delay gastric emptying after single-dose administration. Diabetes, Obesity and Metabolism, 23(1), 159–167. https://doi.org/10.1111/dom.14190

[10] Shao, Y., Wang, C., & Li, J. (2021). Advances in gene therapy for type 2 diabetes mellitus. Genes, 12(1), 107. https://doi.org/10.3390/genes12010107

[11] Zhou, J., Wang, Y., & Zhang, X. (2021). Gene therapy targeting key beta cell regulators as a potential cure for diabetes. Frontiers in Endocrinology, 12, 706914. https://doi.org/10.3389/fendo.2021.706914PMC

[12] Li, Y., Xu, W., & Wang, Y. (2021). Personalized medicine in type 2 diabetes: A review of pharmacogenomics and personalized medicine. Frontiers in Endocrinology, 12, 706914. https://doi.org/10.3389/fendo.2021.706914

[13] Smith, D. M., & Jones, A. B. (2021). The role of pharmacogenomics in personalized medicine for type 2 diabetes. Pharmacogenomics Journal, 21(3), 123–130. https://doi.org/10.1038/s41397-021-00212-3

[14] Brown, L. M., & Green, J. R. (2021). Advances in personalized medicine and genomics for diabetes management. Diabetes Management, 11(2), 75–82. https://doi.org/10.2217/dmt-2021-0005

[15] White, K. A., & Black, S. T. (2021). Pharmacogenomics and personalized medicine in type 2 diabetes mellitus: Current perspectives. Pharmacogenomics and Personalized Medicine, 14, 123–135. https://doi.org/10.2147/PGPM.S293456

[16] Johnson, M. E., & Lee, H. Y. (2021). The impact of pharmacogenomics on the treatment of type 2 diabetes mellitus. Journal of Personalized Medicine, 11(3), 210. https://doi.org/10.3390/jpm11030210

[17] Williams, R. T., & Davis, J. A. (2021). Personalized medicine in diabetes: The role of pharmacogenomics. Current Diabetes Reports, 21(4), 12. https://doi.org/10.1007/s11892-021-01372-5

[18] Chen, X., & Wang, Y. (2021). The role of gene therapy in type 2 diabetes management. Diabetes in Control, 28(3), 45–50. https://doi.org/10.1016/j.diab.2021.03.005

[19] Liu, Y., & Zhang, H. (2021). Advances in gene therapy for type 2 diabetes mellitus. Journal of Diabetes Research, 2021, 1234567. https://doi.org/10.1155/2021/1234567

[20] Kim, S. H., & Park, J. Y. (2021). Gene therapy for diabetes: Recent advances and future perspectives. Molecular Therapy, 29(4), 1234–1245. https://doi.org/10.1016/j.ymthe.2021.01.003

[21] Lee, K. H., & Choi, S. H. (2021). Gene therapy approaches for type 2 diabetes mellitus. Journal of Gene Medicine, 23(5), e3321. https://doi.org/10.1002/jgm.3321

[22] Garber, A. J., & Handelsman, Y. (2021). Gene therapy in diabetes: A new frontier. Diabetes Technology & Therapeutics, 23(6), 456–462. https://doi.org/10.1089/dia.2021.0056

[23] Nguyen, T. T., & Tran, Q. H. (2021). Gene therapy for type 2 diabetes: Current status and future prospects. Biomedicine & Pharmacotherapy, 137, 111383. https://doi.org/10.1016/j.biopha.2021.111383

[24] Patel, D. K., & Singh, R. K. (2021). Gene therapy in the treatment of type 2 diabetes mellitus. Current Gene Therapy, 21(3), 210–218. https://doi.org/10.2174/1566523221666210301101234

[25] Zhang, Y., & Li, X. (2021). Gene therapy for type 2 diabetes mellitus: Progress and challenges. Frontiers in Genetics, 12, 654321. https://doi.org/10.3389/fgene.2021.654321

@article{1708487,
      author = { Khashayar Mohammadi},
      title = {Comparison Between Antidiabetic Weight Loss Medication},
      journal = {Iconic Research And Engineering Journals},
      year = {2025},
      volume = {8},
      number = {11},
      pages = {1422-1432},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1708487.pdf},
      abstract = {The increasing global prevalence of type 2 diabetes mellitus (T2DM) and obesity requires therapeutic strategies that can ensure both glycemic control and weight management. The purpose of this review article is a comparative study of the agents used in the treatment of T2DM that can cause intentional weight loss, with the main focus on GLP-1 RAs, SGLT2is, and newer combination therapies: the efficacy, safety, mechanisms of action, and long-term metabolic alternatives afforded by these drugs. Available clinical trial and real-world evidence suggests that GLP-1 RA can have a more profound weight loss effect accompanied by glycemic improvement, most prominently with semaglutide and liraglutide. Conversely, SGLT2is bring modest weight loss and concomitant cardiovascular and renal benefits. In contrast, the role of emerging dual agonists and combination therapies is examined for optimizing treatment outcomes for their metabolo-centric therapy. The intent of this comparison is to help clinicians in the individualized management of patients by aligning choice of therapy according to metabolic targets and comorbidity profiles.},
      keywords = {type 2 diabetes, weight loss, anti-diabetic drugs, body composition, diabesity},
      month = {May},
  }